Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a PAR4 polynucleotide in a biological system comprising:
- contacting said system with at least one antisense oligonucleotide 12 to 26 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynucleotide of the PAR4 gene and has at least 80% sequence identity to a reverse complement of a natural antisense of a PAR4 polynucleotide;
thereby upregulating a function of and/or the expression of the PAR4 polynucleotide wherein said natural antisense polynucleotide consists essentially of SEQ ID NO;
2.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of PAR4, in particular, by targeting natural antisense polynucleotides of PAR4. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of PAR4.
202 Citations
19 Claims
-
1. A method of upregulating a function of and/or the expression of a PAR4 polynucleotide in a biological system comprising:
- contacting said system with at least one antisense oligonucleotide 12 to 26 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynucleotide of the PAR4 gene and has at least 80% sequence identity to a reverse complement of a natural antisense of a PAR4 polynucleotide;
thereby upregulating a function of and/or the expression of the PAR4 polynucleotide wherein said natural antisense polynucleotide consists essentially of SEQ ID NO;
2. - View Dependent Claims (2, 11)
- contacting said system with at least one antisense oligonucleotide 12 to 26 nucleotides in length wherein said at least one oligonucleotide is specific for and specifically hybridizes to a natural antisense polynucleotide of the PAR4 gene and has at least 80% sequence identity to a reverse complement of a natural antisense of a PAR4 polynucleotide;
-
3. A method of upregulating a function of and/or the expression of a PAR4 polynucleotide in a biological system comprising:
- contacting said system with at least one antisense oligonucleotide of 14 to 24 nucleotides in length that specifically targets and specifically hybridizes to a region of a natural antisense polynucleotide of the PAR4 polynucleotide wherein said natural antisense polynucleotide comprises SEQ ID NO;
2;
thereby upregulating a function of and/or the expression of the PAR4 polynucleotide. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10)
- contacting said system with at least one antisense oligonucleotide of 14 to 24 nucleotides in length that specifically targets and specifically hybridizes to a region of a natural antisense polynucleotide of the PAR4 polynucleotide wherein said natural antisense polynucleotide comprises SEQ ID NO;
-
12. A method of upregulating a function of and/or the expression of a PAR4 gene in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for and specifically hybridizes to a natural antisense polynucleotide of a PAR4 polynucleotide, wherein said at least one siRNA oligonucleotide has at least 80% sequence identity to at least about 19 consecutive nucleic acids of the non-overlapping RNA adjacent to the PAR4 polynucleotide; and
, upregulating a function of author the expression of PAR4 in mammalian cells or tissues in vivo or in vitro. - View Dependent Claims (13)
- contacting said cells or tissues with at least one short interfering RNA (siRNA) oligonucleotide 19 to 30 nucleotides in length, said at least one siRNA oligonucleotide being specific for and specifically hybridizes to a natural antisense polynucleotide of a PAR4 polynucleotide, wherein said at least one siRNA oligonucleotide has at least 80% sequence identity to at least about 19 consecutive nucleic acids of the non-overlapping RNA adjacent to the PAR4 polynucleotide; and
-
14. A method of upregulating a function of and/or the expression of PAR4 in mammalian cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide of about 12 to 24 nucleotides in length specific for and specifically hybridizing to a natural antisense strand of a PAR4 polynucleotide wherein said at least one antisense oligonucleotide has at least 80% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS;
1 or an RNA transcribed from the PAR4 polynucleotide; and
, upregulating the function and/or expression of the PAR4 in mammalian cells or tissues in vivo or in vitro.
- contacting said cells or tissues with at least one antisense oligonucleotide of about 12 to 24 nucleotides in length specific for and specifically hybridizing to a natural antisense strand of a PAR4 polynucleotide wherein said at least one antisense oligonucleotide has at least 80% sequence identity to at least one nucleic acid sequence set forth as SEQ ID NOS;
-
15. A method of preventing or treating a disease associated with at least one PAR4 polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 12 to 24 nucleotides in length that specifically hinds to a natural antisense sequence of said at least one PAR4 polynucleotide and upregulates expression of said at least one PAR4 polynucleotide;
thereby preventing or treating the disease associated with the at least one PAR4 polynucleotide and/or at least one encoded product thereof. - View Dependent Claims (16)
- administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide of 12 to 24 nucleotides in length that specifically hinds to a natural antisense sequence of said at least one PAR4 polynucleotide and upregulates expression of said at least one PAR4 polynucleotide;
- 17. A method of inducing apoptosis in a biological system comprising administration of an oligonucleotide of 14 to 24 nucleotides in length and which is at least 90% identical to 14 to 24 consecutive nucleotides within a reverse complement of a natural antisense transcript to a PAR4 polynucleotide to said system and wherein the natural antisense transcript consists essentially of SEQ ID NO:
-
19. A method of inducing apoptosis in a biological system comprising administration of an oligonucleotide of about 14 to 22 nucleotides in length to said system wherein said oligonucleotide upregulates a target gene by targeting to a natural antisense transcript of the gene and wherein said oligonucleotide is at least 80% identical to a reverse complement of the natural antisense transcript of the upregulated gene and wherein the target gene is a PAR4 gene and the natural antisense transcript comprises SEQ ID NO:
- 2.
Specification